Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations.

[1]  Johnny C. Hong,et al.  Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. , 1999, Transplantation.

[2]  B. Kahan.  PIVOTAL PHASE III MULTICENTER, RANDOMIZED, BLINDED TRIAL OF SIROLIMUS VERSUS AZATHIOPRINE IN COMBINATION WITH CYCLOSPORINE AND PREDNISONE IN PRIMARY RENAL TRANSPLANTS , 1999 .

[3]  J. Jaffe,et al.  TRIGLYCERIDE (TG) ELEVATIONS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH SIROLIMUS (RAPAMYCIN, RAPA) ADDED TO A CYCLOSPORINE (CsA)/PREDNISONE (PRED) REGIMEN , 1999 .

[4]  J. Camardo,et al.  KINETIC-DYNAMIC CORRELATIONS OF SIROLIMUS AND CYCLOSPORINE IN 438 PRIMARY RENAL TRANSPLANT RECIPIENTS , 1999 .

[5]  R. Calne,et al.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. , 1999, Transplantation.

[6]  S. Stepkowski,et al.  SIROLIMUS EXACERBATES CsA-INDUCED NEPHROTOXICITY BY RAISING CsA BLOOD TROUGH LEVELS, BUT DOES NOT IMPAIR RENAL FUNCTION BY A PHARMACODYNAMIC INTERACTION , 1999 .

[7]  A. Macdonald.  A RANDOMIZED TRIAL OF SIROLIMUS, CYCLOSPORINE AND PREDNISONE VS CYCLOSPORINE - PREDNISONE ALONE IN RECIPIENTS OF MISMATCHED FIRST KIDNEY GRAFTS: RESULTS AT ONE YEAR , 1999 .

[8]  C. Marboe,et al.  Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. , 1999, The Journal of thoracic and cardiovascular surgery.

[9]  R. Sindhi,et al.  OUTCOMES OF AFRICAN AMERICANS (AA) IN A PHASE III RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SIROLIMUS (SRL) IN RENAL TRANSPLANTATION , 1999 .

[10]  D. Urbauer,et al.  PHARMACOKINETIC AND PHARMACODYNAMIC CORRELATIONS OF CYCLOSPORINE (CsA) AND RAPAMYCIN (RAPA) IN 120 PATIENTS TREATED FOR AT LEAST 2 YEARS AT A SINGLE CENTER. , 1999 .

[11]  Junzheng Peng,et al.  Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. , 1998, Transplantation.

[12]  H. Meier‐Kriesche,et al.  Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation , 1998 .

[13]  S. Stepkowski,et al.  Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. , 1998, Therapeutic drug monitoring.

[14]  H. Meier‐Kriesche,et al.  The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent , 1998, Clinical pharmacology and therapeutics.

[15]  B. Kahan,et al.  Pharmacokinetics of Sirolimus in Stable Renal Transplant Patients after Multiple Oral Dose Administration , 1997, Journal of clinical pharmacology.

[16]  B D Kahan,et al.  Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection , 1997, Clinical and experimental immunology.

[17]  W. Jusko,et al.  Population pharmacokinetics of sirolimus in kidney transplant patients , 1997, Clinical pharmacology and therapeutics.

[18]  S. Stepkowski,et al.  Distribution of sirolimus in rat tissue. , 1997, Clinical biochemistry.

[19]  B D Kahan,et al.  Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. , 1996, Transplantation.

[20]  W. Bennett,et al.  Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. , 1996, Kidney international.

[21]  W. Bennett,et al.  Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. , 1996, Transplantation.

[22]  A. Matas,et al.  A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. , 1996, Transplantation proceedings.

[23]  R. Yatscoff,et al.  Rapamycin: Distribution, Pharmacokinetics, and Therapeutic Range Investigations , 1995, Therapeutic drug monitoring.

[24]  M. Mihatsch,et al.  Renal effects of rapamycin in the spontaneously hypertensive rat , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[25]  D. Finegood,et al.  PROLONGATION OF CANINE PANCREATIC ISLET ALLOGRAFT SURVIVAL WITH COMBINED RAPAMYCIN AND CYCLOSPORINE THERAPY AT LOW DOSES: RAPAMYCIN EFFICACY IS BLOOD LEVEL RELATED1 , 1993, Transplantation.

[26]  J. Thliveris,et al.  THE RELATIONSHIP OF BLOOD CONCENTRATIONS OF RAPAMYCIN AND CYCLOSPORINE TO SUPPRESSION OF ALLOGRAFT REJECTION IN A RABBIT HETEROTOPIC HEART TRANSPLANT MODEL1 , 1993, Transplantation.

[27]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[28]  R. Martel,et al.  Inhibition of the immune response by rapamycin, a new antifungal antibiotic. , 1977, Canadian journal of physiology and pharmacology.